MX2021009535A - Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación. - Google Patents

Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.

Info

Publication number
MX2021009535A
MX2021009535A MX2021009535A MX2021009535A MX2021009535A MX 2021009535 A MX2021009535 A MX 2021009535A MX 2021009535 A MX2021009535 A MX 2021009535A MX 2021009535 A MX2021009535 A MX 2021009535A MX 2021009535 A MX2021009535 A MX 2021009535A
Authority
MX
Mexico
Prior art keywords
treatment
radiation dermatitis
braf inhibitor
inhibitor compositions
topical
Prior art date
Application number
MX2021009535A
Other languages
English (en)
Inventor
Noa Shelach
Noa Lowenton-Spier
Original Assignee
Lutris Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lutris Pharma Ltd filed Critical Lutris Pharma Ltd
Publication of MX2021009535A publication Critical patent/MX2021009535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención divulga métodos de tratamiento, prevención y/o mejora de la dermatitis por radiación causada por radioterapia, mediante la administración a un sujeto que lo necesita de una composición tópica que comprende una cantidad terapéutica o profilácticamente efectiva de al menos un inhibidor de BRaf de esta invención, con lo cual se pueden tratar, prevenir y/o mejorar los efectos de la dermatitis por radiación.
MX2021009535A 2019-02-12 2020-02-11 Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación. MX2021009535A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962804235P 2019-02-12 2019-02-12
PCT/IB2020/051073 WO2020165755A1 (en) 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis

Publications (1)

Publication Number Publication Date
MX2021009535A true MX2021009535A (es) 2022-10-10

Family

ID=72044789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009535A MX2021009535A (es) 2019-02-12 2020-02-11 Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.

Country Status (17)

Country Link
US (1) US11439648B2 (es)
EP (1) EP3923911B1 (es)
JP (1) JP2022519675A (es)
KR (1) KR102534457B1 (es)
CN (1) CN113382717A (es)
AU (1) AU2020220895B9 (es)
BR (1) BR112021015137A2 (es)
CA (1) CA3127175C (es)
ES (1) ES2952251T3 (es)
HR (1) HRP20231241T1 (es)
HU (1) HUE063091T2 (es)
IL (1) IL285560B2 (es)
MX (1) MX2021009535A (es)
PL (1) PL3923911T3 (es)
RS (1) RS64618B1 (es)
WO (1) WO2020165755A1 (es)
ZA (1) ZA202106581B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203021A1 (en) * 2020-12-24 2022-06-30 Noa Shelach Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions
WO2023275620A2 (en) * 2021-07-02 2023-01-05 Lutris Pharma Ltd. Use of isoquinoline-1,5-diamines for wound healing
WO2023051685A1 (zh) * 2021-09-30 2023-04-06 北京大学 一种对红系前体细胞或成红细胞进行扩增的方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP2170887A2 (en) 2007-06-07 2010-04-07 Amgen Inc. Heterocyclic compounds as raf kinase modulators
HUE032873T2 (en) * 2008-03-17 2017-11-28 Ambit Biosciences Corp 1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
WO2011117381A1 (en) * 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
TWI611053B (zh) 2012-02-27 2018-01-11 曾宇鳳 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
WO2017154001A1 (en) * 2016-03-10 2017-09-14 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions
KR102328351B1 (ko) * 2017-07-29 2021-11-19 루트리스 파마 엘티디. 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도
CA3072200A1 (en) * 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor

Also Published As

Publication number Publication date
JP2022519675A (ja) 2022-03-24
CN113382717A (zh) 2021-09-10
US20210346389A1 (en) 2021-11-11
EP3923911A1 (en) 2021-12-22
US11439648B2 (en) 2022-09-13
EP3923911C0 (en) 2023-07-12
AU2020220895B2 (en) 2022-11-17
EP3923911B1 (en) 2023-07-12
EP3923911A4 (en) 2022-11-09
RS64618B1 (sr) 2023-10-31
BR112021015137A2 (pt) 2021-09-28
AU2020220895B9 (en) 2023-02-02
CA3127175C (en) 2023-06-27
HRP20231241T1 (hr) 2024-02-16
IL285560B2 (en) 2024-04-01
WO2020165755A1 (en) 2020-08-20
PL3923911T3 (pl) 2023-12-27
KR102534457B1 (ko) 2023-05-18
ZA202106581B (en) 2022-09-28
KR20210126665A (ko) 2021-10-20
IL285560A (en) 2021-09-30
IL285560B1 (en) 2023-12-01
CA3127175A1 (en) 2020-08-20
AU2020220895A1 (en) 2021-08-12
ES2952251T3 (es) 2023-10-30
HUE063091T2 (hu) 2024-01-28

Similar Documents

Publication Publication Date Title
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
MX2021008751A (es) Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2017011037A (es) Bacteria manejada geneticamente para tratar enfermedades que se benefician de inflamacion intestinal reducida y/o barrera mucosa intestinal fortalecida.
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2021008974A (es) Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof.
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
MX2021014175A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
EP4275761A3 (en) Alkaline phosphatase agents for treatment of radiation disorders
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
WO2015035410A8 (en) Cancer therapy
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
NZ743894A (en) Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia